This is of particular interest in drug development strategies as both CXCR4 and STAT3 antagonisms have been proposed as broad spectrum target in cancer therapy (Wang et al, 2006; Germain and Frank, 2007; Ruffini et al, 2007). This evidence concerns the gene CXCR4 and cancer.